The current state and future directions of RNAi-based therapeutics
Setten RL, Rossi JJ, Han S · Nature Reviews Drug Discovery, 2019
Setten RL, Rossi JJ, Han S
A comprehensive review of RNA interference as a drug class, written as the first siRNA medicines reached the clinic. It covers design, chemical modification, delivery beyond the liver and the clinical pipeline, giving a clear map of where the field stood and the problems still to solve. A useful orientation for anyone entering siRNA drug development.
Related in the Knowledge Hub
From theory to a synthesis ready oligo
Syngenis One designs, screens and orders custom oligonucleotides in one guided workflow. Talk to our team or start designing today.
One engine, working across the whole business.
Syngenis One (AI Discovery)
Design RNA and DNA candidates from target to synthesis ready oligo in one workflow.
Manufacturing
Australia's only commercial RNA facility. Custom oligonucleotides, ordered through Syngenis One.
Research and Diagnostics
AI led therapeutic programs and an aptamer based diagnostics pipeline.
Clinical
A specialist nucleic acid CRO with in silico trial modelling.
Life Care
Consumer genomics at a mass market price.
Fund
Infrastructure that channels research investment into the pipeline.